ECSP23090260A - Compuestos indol sustituidos y métodos de uso de los mismos - Google Patents

Compuestos indol sustituidos y métodos de uso de los mismos

Info

Publication number
ECSP23090260A
ECSP23090260A ECSENADI202390260A ECDI202390260A ECSP23090260A EC SP23090260 A ECSP23090260 A EC SP23090260A EC SENADI202390260 A ECSENADI202390260 A EC SENADI202390260A EC DI202390260 A ECDI202390260 A EC DI202390260A EC SP23090260 A ECSP23090260 A EC SP23090260A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
substituted indol
inhibitors
complement
Prior art date
Application number
ECSENADI202390260A
Other languages
English (en)
Inventor
Victoria Elizabeth Rose
Brian P Bestvater
Jinyue Ding
Robert Gomez
Nicholas Anton Mateyko
David Andrew Powell
Tao Sheng
Taro Oike
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Publication of ECSP23090260A publication Critical patent/ECSP23090260A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona compuestos indol sustituidos. En ciertas formas de realización, los compuestos son inhibidores de la vía alternativa del sistema del complemento y, en particular, inhibidores del factor B del complemento. (CFB). Además se proporcionan composiciones que comprenden los compuestos y métodos de uso de los mismos. Los compuestos proporcionados son útiles en el tratamiento, prevención o mejora de una enfermedad, afección o trastorno mediante la inhibición de la vía alternativa del complemento.
ECSENADI202390260A 2021-06-03 2023-11-30 Compuestos indol sustituidos y métodos de uso de los mismos ECSP23090260A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196339P 2021-06-03 2021-06-03
US202163290019P 2021-12-15 2021-12-15
US202263346120P 2022-05-26 2022-05-26

Publications (1)

Publication Number Publication Date
ECSP23090260A true ECSP23090260A (es) 2024-02-29

Family

ID=84323595

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202390260A ECSP23090260A (es) 2021-06-03 2023-11-30 Compuestos indol sustituidos y métodos de uso de los mismos

Country Status (15)

Country Link
US (1) US20240287034A1 (es)
EP (1) EP4346812A2 (es)
JP (1) JP2024521878A (es)
KR (1) KR20240017004A (es)
AU (1) AU2022283903A1 (es)
BR (1) BR112023025235A2 (es)
CA (1) CA3222144A1 (es)
CL (1) CL2023003591A1 (es)
CO (1) CO2023016557A2 (es)
CR (1) CR20230564A (es)
DO (1) DOP2023000263A (es)
EC (1) ECSP23090260A (es)
IL (1) IL308835A (es)
MX (1) MX2023014274A (es)
WO (1) WO2022256586A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236104A1 (en) * 2021-10-27 2023-05-04 Hugh Y. Zhu Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
AU2023209631A1 (en) * 2022-01-24 2024-07-25 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
WO2023237012A1 (zh) * 2022-06-07 2023-12-14 正大天晴药业集团股份有限公司 双环取代的芳香羧酸类氘代化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
WO2024049977A1 (en) * 2022-08-31 2024-03-07 Chinook Therapeutics, Inc. Substituted indole compounds and methods of use thereof
WO2024051849A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
WO2024104292A1 (en) * 2022-11-14 2024-05-23 Novartis Pharma Ag Solid forms of complement factor b inhibitors
WO2024114677A1 (zh) * 2022-11-29 2024-06-06 上海济煜医药科技有限公司 苯并螺环吲哚化合物的制备、应用及用途
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
WO2024149261A1 (zh) * 2023-01-09 2024-07-18 南京正大天晴制药有限公司 补体因子b抑制剂
WO2024169896A1 (zh) * 2023-02-16 2024-08-22 西藏海思科制药有限公司 一种苯并氮杂芳环衍生物的盐、晶型及其在医药上的应用
WO2024175028A1 (zh) * 2023-02-22 2024-08-29 西藏海思科制药有限公司 一种苯并氮杂芳环衍生物的药物组合物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2647124T3 (es) * 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AU2017290593A1 (en) * 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도

Also Published As

Publication number Publication date
WO2022256586A3 (en) 2023-01-12
IL308835A (en) 2024-01-01
DOP2023000263A (es) 2024-02-29
MX2023014274A (es) 2024-04-22
KR20240017004A (ko) 2024-02-06
BR112023025235A2 (pt) 2024-02-27
CA3222144A1 (en) 2022-12-08
US20240287034A1 (en) 2024-08-29
CL2023003591A1 (es) 2024-06-28
CO2023016557A2 (es) 2024-02-26
WO2022256586A2 (en) 2022-12-08
EP4346812A2 (en) 2024-04-10
AU2022283903A1 (en) 2023-11-30
JP2024521878A (ja) 2024-06-04
CR20230564A (es) 2024-02-27

Similar Documents

Publication Publication Date Title
CO2023016557A2 (es) Compuestos indol sustituidos y métodos de uso de los mismos
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
UY38403A (es) Moduladores de la alfa-1 antitripsina
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue
NI201800040A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
NI201800039A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
DOP2019000184A (es) Inhibidores selectivos de jak1
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CR20220199A (es) Inhibidores del factor d del complemento para administración oral
CU24707B1 (es) Inihibidores del factor d del complemento para administración oral
CO2023015732A2 (es) Moduladores de trex1
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
ECSP18008411A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc